Pharma BD Deal Intelligence
Duality Biologics and GSK enter exclusive option agreement for novel antibody-drug conjugate DB-1324 worth up to $975 million
GSK gains exclusive option on DualityBio preclinical ADC in deal worth over $1 billion leveraging proprietary DITAC platform technology
Goodwin advises Duality Biologics on exclusive option agreement with GSK for novel antibody-drug conjugate DB-1324 worth up to $975 million
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK obtained an exclusive option on DualityBio's ADC candidate DB-1324, built on the DITAC platform and targeting a gastrointestinal-cancer target. GSK paid $30M upfront plus pre-option milestones; upon option exercise DualityBio is eligible for an exercise fee plus up to $975M in development, regulatory and commercial milestones plus tiered royalties, for exclusive worldwide rights ex-Greater China (mainland China, Hong Kong, Macau). Since signing, DB-1324 has advanced from preclinical to the clinic: DualityBio reported U.S. FDA IND clearance (Dec 2025) and opened its first-in-human Phase 1/2 study (NCT07263594; study start Jan 2026, 127 patients) in advanced/metastatic GI tumors. As of this review there is no public disclosure that GSK has exercised or terminated the option.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Duality Biologics (Suzhou) Co. Ltd. (this deal) | 2024 | $975M | 61 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2024 deals · GSK plc deals · Oncology deals